Firefly Neuroscience

Brain Network Analytics (BNA) provides insights into neural activity for clinical care and practice efficiency.

See how Firefly measures brain function in a 30 to 45 minute in-office assessment and compares it to 191,000+ age-matched recordings to guide care.

Peer-reviewed research using Firefly's BNA technology in major depression, cognitive assessment, concussion and early-stage Parkinson's disease.

Firefly Neuroscience completed a Nasdaq listing through a $45 million reverse merger with WaveDancer, expanding financing options for its AI-powered brain function measurement platform.

Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology.

Zeto and Firefly Neuroscience have partnered to distribute Zeto’s FDA-cleared EEG headsets, the WR19 and Zeto ONE. The agreement includes integration of Firefly’s Brain Network Analytics (BNA) technology.

Firefly Neuroscience has partnered with Neurology Consultants of Dallas to improve early detection and management of cognitive decline in patients.

Firefly Neuroscience offers career opportunities in psychiatry and neurology, focusing on brain function data.

Firefly Neuroscience introduces its leadership team, including CEO Greg Lipschitz, President and COO Dave DeCaprio, CFO Paul Krzywicki, and CTO Gil Issachar.

Firefly Neuroscience brings objective brain function data into psychiatry and neurology care, so clinicians see how the brain works, not just symptoms.

Firefly Neuroscience provides product demos for its Brain Network Analytics (BNA) technology.

Firefly Neuro delivers FDA-cleared brain health technology, using EEG and ERP to help clinicians detect, diagnose, and monitor neurological conditions with greater clarity.